Streetbeat News

Stock Prices

PLTR

SMMT

TERN

Palantir Technologies (PLTR) shares rose 8% due to its addition to the S&P 500 index. Terns Pharmaceuticals (TERN) saw a 42% increase after announcing positive Phase 1 trial results for TERN-601. Summit Therapeutics (SMMT) shares surged 62% following successful trial results for Ivonescimab in treating advanced NSCLC.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 12:09 pm

CVX

DRIP

FANG

GUSH

MTDR

PR

XOM

Chevron and Exxon Mobil saw slight pre-market gains after last week's losses due to economic concerns. Direxion's leveraged oil ETFs, GUSH and DRIP, offer opportunities for bullish and bearish investors, respectively. GUSH is below key moving averages, while DRIP has gained due to falling oil prices.

Portfolio Pulse from Joshenomoto@benzinga.com

September 09, 2024 | 12:08 pm

ACTU

Actuate Therapeutics announced that its drug Elraglusib showed promising results in treating relapsed/refractory Ewing and Ewing-related sarcomas. In the first 8 patients, the drug achieved a 62% disease control rate and two ongoing durable complete responses.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 12:07 pm

CTMX

CytomX Therapeutics has dosed the first patient in a Phase 1 study of CX-801, targeting solid tumors. This marks a significant milestone in their clinical development program.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 12:06 pm

EVAX

Evaxion Biotech announced interim results from its Phase 2 trial of EVX-01, showing a 69% overall response rate with 15 out of 16 patients experiencing tumor reduction.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 12:05 pm

WEX

WEX's Board of Directors has authorized a $1 billion increase to its share buyback program, indicating confidence in the company's financial health and future prospects.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 12:03 pm

ANNX

Annexon, Inc. presented promising Phase 2 data for ANX007, a treatment for geographic atrophy, showing significant vision protection and photoreceptor preservation. The Phase 3 program is underway with results expected in 2026.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 12:03 pm

MRK

SMMT

Summit Therapeutics' ivonescimab shows promising results in a Phase 3 trial, outperforming Merck's Keytruda in treating non-small cell lung cancer. The trial demonstrated significant improvements in progression-free survival and response rates. Summit plans further trials to confirm these findings.

Portfolio Pulse from Vandana Singh

September 09, 2024 | 12:03 pm

RBLX

Roblox (NYSE:RBLX) has received mixed analyst ratings over the past three months, with a recent increase in average price targets. Analysts have raised their ratings and price targets, reflecting a positive sentiment shift. Despite strong revenue growth, Roblox faces challenges with profitability, ROE, ROA, and high debt levels.

Portfolio Pulse from Benzinga Insights

September 09, 2024 | 12:01 pm

TCBI

Texas Capital Bancshares (NASDAQ:TCBI) has received mixed analyst ratings over the past three months, with a recent positive shift in average price targets. Analysts have raised their price targets, reflecting a more optimistic outlook despite the company's financial challenges, such as declining revenue and below-average profitability metrics.

Portfolio Pulse from Benzinga Insights

September 09, 2024 | 12:01 pm